Skip to main content

Articles By Jack Cush, MD

TNF%20blockers.jpg

ICYMI: TNF Inhibitor Drug-Induced Lupus

A study from the FDA's adverse event reporting system (FAERS or Medwatch) database identified cases of drug induced systemic lupus erythematosus (SLE) in patients receiving tumor necrosis factor-α (TNF-α) inhibitors - a paradoxical reaction to common antiinflammatory biologic agents.

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

ICYMI: Is Rheumatoid Arthritis Becoming Milder?

A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.

Read Article
LBP_0.jpg

ICYMI: Axial Involvement in Psoriatic Arthritis

Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.

Read Article
RheumNow Podcast square

PCR: Prevalence, Cost, & Risk (6.27.2025)

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Read Article
lab.test.genetics.lavender.pcr

HLA-B27 Testing in Practice

A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined.

Read Article
epilepsy,brain,seizure,CVA

A Review of Intracranial GCA

A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.

Read Article
RheumNow Podcast square

Trends and Innovations from Barcelona (6.20.2025)

Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.

Read Article
eular

EULAR 2025 – Day 4 Report

Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following.

Read Article
acr_session2.jpeg

EULAR 2025 – Day 3 Report

Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.

Read Article
EULAR,poster

EULAR 2025 – Day 2 Report

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.

Read Article
×